logo RLK Srbije eng

Pharmacology - Serbian Journal of the Medical Chamber

Anticoagulants and corticosteroids in COVID-19 – what do we know so far?

INTRODUCTION The first cases of atypical pneumonia caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) were registered in December 2019, in Wuhan (China) [1]. The disease very quickly spread all over the world and, on March 11, 2020, the World Health Organization declared the coronavirus...

Impact of the COVID-19 pandemic on chronic pain management

  • Citiranje članka: 4
INTRODUCTION Over the past eighteen months, the coronavirus disease 2019 (COVID-19) pandemic has caused dramatic societal, economic, and healthcare disruptions across the world. As of June 20th, 2021, in the United States alone, a total of 33,368,860 cases of COVID-19 have been reported, along with...

Methylprednisolone therapy in acute spinal cord injuries

INTRODUCTION Spinal cord injuries are a significant medical and socio-economic problem. The patients are often young individuals with a severe neurological deficit (type: quadri- or paraplegia, i.e., paresis), which is permanent in character, and which carries with it the development of secondary...

Pharmacogenetics of antidepressants – A step to individualized therapy

INTRODUCTION Depressive disorders are among the most common diseases today, with more than 350 million patients and an annual prevalence of 4.7% globally [1,2]. They are the most common mental disorders in the general population, with an incidence twice as high among women as among men. Depressive...

Thrombocytopenia and COVID-19: differential diagnosis and therapy

INTRODUCTION Over the past two years, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes coronavirus disease 2019 (COVID-19), has led to the infection of millions of people all over the world, and, according to data from November 2021, it has also led to more than five million...

© All rights reserved. Medical Chamber of Serbia.

To top